GentiBio
Vicki is a Senior Scientist at GentiBio. She is an Immunologist by training completing her BS in Biology and Biotechnology at Worcester Polytechnic Institute, and Ph.D. at the University of Vermont where she focused on genetic factors that determined NKT cell function. Before Genti, Vicki worked at Genocea Biosciences both as an RA before graduate school on the infectious disease screening team, and after graduate school where she helped investigate the biology and mechanism of action of Inhibigens- neoantigens that seemingly shutdown anti-tumor immune responses. She has always been interested in non-conventional T cells and is excited to help harness Tregs in a beneficial way.
GentiBio
GentiBio, Inc., is an early stage biotherapeutics company co-founded by pioneers in Treg biology and synthetic immunology to develop engineered regulatory T cells (EngTregs) programmed to treat autoimmune, alloimmune, autoinflammatory and allergic diseases. GentiBio's proprietary autologous and allogeneic EngTregs platform integrates key complimentary technologies needed to successfully restore immune tolerance and overcome major limitations in existing regulatory T-cell therapeutics. GentiBio is at the forefront of leveraging a unique therapeutic modality that can be used to address the fundamental cause of many diseases that result from overshooting and/or malfunctioning of the immune system.